Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

Rhea-AI Summary

Zai Lab Limited (NASDAQ: ZLAB) announced it will report financial results for Q3 2022 on November 9, 2022, after market close. A conference call and webcast will be held on November 10, 2022, at 8:00 a.m. ET, where the company will provide corporate updates. Investors can register in advance through the provided link. Zai Lab is committed to delivering innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.

Positive

• Upcoming Q3 2022 financial results reporting may provide insight into company performance.

Negative

• None.

-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended September 30, 2022, after the closing of the U.S. equity markets on November 9, 2022. The Company will host a live conference call and webcast on November 10, 2022, at 8:00 a.m. ET.

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:

Registration Link: https://register.vevent.com/register/BI98db73679f254c8eb1024c9df5ea85a8

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com and follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media: Christine Drury / Xiaoyu Chen
+1 (317) 385-9227 / +86 185 0015 5011
christine.drury@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited

FAQ

When will Zai Lab report its Q3 2022 financial results?

Zai Lab will report its Q3 2022 financial results on November 9, 2022, after the market closes.

What time is the conference call for Zai Lab's Q3 2022 results?

The conference call will be held on November 10, 2022, at 8:00 a.m. ET.

How can I access Zai Lab's conference call?

Participants can access the conference call by registering through the provided link on Zai Lab's investor relations page.

What is Zai Lab known for?

Zai Lab is a biopharmaceutical company focused on developing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.